Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
268 daily bars · split adjusted
Current price $2.32
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.67 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 36.84 | Oscillator | Neutral |
| Williams %R (14) | -68.42 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.08 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 53.35 (+DI 26.5 / -DI 11.9) | Trend | Strong Buy |
| EMA 20 | 2.41 | MA | Strong Sell |
| SMA 20 | 2.38 | MA | Sell |
| EMA 50 | 2.93 | MA | Strong Sell |
| SMA 50 | 2.57 | MA | Strong Sell |
| SMA 200 | 12.41 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 3, 26 | Wang Li (Alya) | officer: COO | 0 | — | |
| Aug 3, 26 | Zhu Xiaoyan | officer: CFO | A-Award | 112,500 @ $0.18 | $20.25K |
| Dec 30, 24 | Shan Yanan | director: | 0 | — | |
| Dec 30, 24 | Li Xinyu | officer: CTO | 0 | — | |
| Dec 30, 24 | Yu Xiaozhong | director: | 0 | — | |
| Dec 30, 24 | Zhu Xiaoyan | officer: CFO | 0 | — | |
| Dec 30, 24 | Zhang Xiaoqiu | director, 10 percent owner, officer: CEO | 0 | — | |
| Dec 30, 24 | Sheng Qixiong | director: | 0 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | BYAH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | 16.0x · sector 37.7x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 0.3x | 17.1x | Discount |
| Price / Sales | 0.5x | 7.0x | Discount |
| EV / EBITDA | -0.2x | 10.1x | Discount |
| Return on equity | -174.2% | — | Weak |
| Gross margin | 89.9% | 82.7% | In line |
| Debt / Equity | 0.03 | 0.05 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -6.51 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
BYAH allegedly structured its IPO with a public float of just 1,200,000 shares, representing less than 5% of the company, a structure the lawsuit contends enabled coordinated price manipulation before BYAH shares collapsed 93% in one session. BYAH allegedly structured its IPO with a public float of just 1,200,000 shares, representing less than 5% of the company, a structure the lawsuit contends enabled coordinated price manipulation before BYAH shares collapsed 93% in one session.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025, inclusive (the “Class Period”). Park Ha develops and sells skincare and cosmetics products.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is.
New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH) (NASDAQ: BYAH) between December 27, 2024 and July 8, 2025, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
BYAH CFO Xiaoyan Zhu since 2016 signed the December 2024 registration statement that the lawsuit contends omitted the promotional scheme behind BYAH's 93% stock collapse. NEW YORK, Sept.
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
Reported EPS vs. consensus estimate